[{"orgOrder":0,"company":"Assembly Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Vebicorvir","moa":"||Core antigen","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Assembly Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Assembly Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Assembly Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Antios Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"ATI-2173","moa":"||Hepatitis B virus Polymerase (HBV P)","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Antios Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Antios Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Antios Therapeutics \/ Undisclosed"}]

Find Clinical Drug Pipeline Developments & Deals for Tenofovir

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Organic Process R&D
                          Not Confirmed
                          Organic Process R&D
                          Not Confirmed

                          Details : ABI-H0731 (Vebicorvir) a first-generation selective inhibition of HBV DNA replication core protein, has demonstrated effective antiviral activity in chronic hepatitis B patients.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          June 08, 2022

                          Lead Product(s) : Vebicorvir,ATI-2173,Tenofovir

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Organic Process R&D
                          Not Confirmed
                          Organic Process R&D
                          Not Confirmed

                          Details : ATI-2173, once-daily, oral drug candidate for treating HBV, is an investigational phosphoramidate prodrug of clevudine monophosphate, only active site polymerase inhibitor nucleotide for HBV in clinical development.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          April 26, 2022

                          Lead Product(s) : ATI-2173,Tenofovir,Vebicorvir

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Wits Health Consortium

                          Country arrow
                          Organic Process R&D
                          Not Confirmed

                          Wits Health Consortium

                          Country arrow
                          Organic Process R&D
                          Not Confirmed

                          Lead Product(s) : Tenofovir

                          Therapeutic Area : Infections and Infectious Diseases

                          Study Phase : Phase II

                          Sponsor : University of Cape Town | University of Liverpool | Imperial College London | MRC/UVRI Uganda Research Unit | Karolinska Institutet | King's College London | London School of Hygiene & Tropical Medicine

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Tenofovir is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of HIV Infections.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          June 14, 2019

                          Lead Product(s) : Tenofovir

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : University of Cape Town | University of Liverpool | Imperial College London | MRC/UVRI Uganda Research Unit | Karolinska Institutet | King's College London | London School of Hygiene & Tropical Medicine

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          CONRAD

                          Country arrow
                          Organic Process R&D
                          Not Confirmed

                          CONRAD

                          Country arrow
                          Organic Process R&D
                          Not Confirmed

                          Lead Product(s) : Tenofovir

                          Therapeutic Area : Undisclosed

                          Study Phase : Phase I

                          Sponsor : United States Agency for International Development | Agility Clinical

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Tenofovir is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          September 12, 2017

                          Lead Product(s) : Tenofovir

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Sponsor : United States Agency for International Development | Agility Clinical

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          CONRAD

                          Country arrow
                          Organic Process R&D
                          Not Confirmed

                          CONRAD

                          Country arrow
                          Organic Process R&D
                          Not Confirmed

                          Lead Product(s) : Tenofovir

                          Therapeutic Area : Infections and Infectious Diseases

                          Study Phase : Phase I

                          Sponsor : Eastern Virginia Medical School | University of North Carolina | Agility Clinical

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Tenofovir is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of HIV Infections.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          March 30, 2016

                          Lead Product(s) : Tenofovir

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I

                          Sponsor : Eastern Virginia Medical School | University of North Carolina | Agility Clinical

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          David Garcia Cinca

                          Country arrow
                          Organic Process R&D
                          Not Confirmed

                          David Garcia Cinca

                          Country arrow
                          Organic Process R&D
                          Not Confirmed

                          Details : Tenofovir is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of HIV Infections.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          October 28, 2015

                          Lead Product(s) : Tenofovir

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Sponsor : Fundació Clínic per a la Recerca Biomèdica

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          Organic Process R&D
                          Not Confirmed
                          Organic Process R&D
                          Not Confirmed

                          Details : Tenofovir is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Burkitt Lymphoma.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          October 26, 2015

                          Lead Product(s) : Tenofovir

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase IV

                          Sponsor : Gilead Sciences | Konkuk University Hospital

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          TetraLogic Pharmaceuticals

                          Country arrow
                          Organic Process R&D
                          Not Confirmed

                          TetraLogic Pharmaceuticals

                          Country arrow
                          Organic Process R&D
                          Not Confirmed

                          Details : Tenofovir is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Hepatitis B.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          November 11, 2014

                          Lead Product(s) : Tenofovir

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          ANRS, Emerging Infectious Diseases

                          Country arrow
                          Organic Process R&D
                          Not Confirmed

                          ANRS, Emerging Infectious Diseases

                          Country arrow
                          Organic Process R&D
                          Not Confirmed

                          Details : Tenofovir is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of HIV Infections.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          October 24, 2014

                          Lead Product(s) : Tenofovir

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Sponsor : Merck & Co | Ministry of Health, Brazil

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          Unity Health Toronto

                          Country arrow
                          Organic Process R&D
                          Not Confirmed

                          Unity Health Toronto

                          Country arrow
                          Organic Process R&D
                          Not Confirmed

                          Lead Product(s) : Tenofovir

                          Therapeutic Area : Infections and Infectious Diseases

                          Study Phase : Phase IV

                          Sponsor : Hassle Free Clinic | Maple Leaf Research | Toronto Metropolitan University | AIDS Committee of Toronto | Canadian AIDS Treatment Information Exchange | Gilead Sciences

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Tenofovir is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of HIV Infections.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          May 29, 2014

                          Lead Product(s) : Tenofovir

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase IV

                          Sponsor : Hassle Free Clinic | Maple Leaf Research | Toronto Metropolitan University | AIDS Committee of Toronto | Canadian AIDS Treatment Information Exchange | Gilead Sciences

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank